If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Don't Surrender to the Index Funds
Trader Be Nimble, Trader Be Quick
PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics